Polymorphisms in genes involved in estrogen and progesterone metabolism and mammographic density changes in women randomized to postmenopausal hormone therapy: results from a pilot study by Lord, Sarah J et al.
Open Access
Available online http://breast-cancer-research.com/content/7/3/R336
R336
Vol 7 No 3 Research article
Polymorphisms in genes involved in estrogen and progesterone 
metabolism and mammographic density changes in women 
randomized to postmenopausal hormone therapy: results from a 
pilot study
Sarah J Lord1, Wendy J Mack1, David Van Den Berg1, Malcolm C Pike1, Sue A Ingles1, 
Christopher A Haiman1, Wei Wang1, Yuri R Parisky3, Howard N Hodis2 and Giske Ursin1,4
1Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
2Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 
USA
3Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
4Department of Nutrition, University of Oslo, Norway
Corresponding author: Giske Ursin, gursin@usc.edu
Received: 20 Sep 2004 Revisions requested: 9 Nov 2004 Revisions received: 6 Dec 2004 Accepted: 13 Jan 2005 Published: 23 Feb 2005
Breast Cancer Research 2005, 7:R336-R344 (DOI 10.1186/bcr999)
This article is online at: http://breast-cancer-research.com/content/7/3/R336
© 2005 Lord et al.; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/
2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Mammographic density is a strong independent
risk factor for breast cancer, and can be modified by hormonal
exposures. Identifying genetic variants that determine increases
in mammographic density in hormone users may be important in
understanding hormonal carcinogenesis of the breast.
Methods We obtained mammograms and DNA from 232
postmenopausal women aged 45 to 75 years who had
participated in one of two randomized, double-blind clinical trials
with estrogen therapy (104 women, taking 1 mg/day of
micronized 17β-estradiol, E2), combined estrogen and
progestin therapy (34 women, taking 17β-estradiol and 5 mg/
day of medroxyprogesterone acetate for 12 days/month) or
matching placebos (94 women). Mammographic percentage
density (MPD) was measured on baseline and 12-month
mammograms with a validated computer-assisted method. We
evaluated polymorphisms in genes involved in estrogen
metabolism (catechol-O-methyltransferase (COMT
(Val158Met)), cytochrome P450 1B1 (CYP1B1 (Val432Leu)),
UDP-glucuronosyltransferase 1A1 (UGT1A1  (<7/≥ 7 TA
repeats))) and progesterone metabolism (aldo-keto reductase
1C4 (AKR1C4 (Leu311Val))) with changes in MPD.
Results The adjusted mean change in MPD was +4.6% in the
estrogen therapy arm and +7.2% in the combined estrogen and
progestin therapy arm, compared with +0.02% in the placebo
arm (P  = 0.0001). None of the genetic variants predicted
mammographic density changes in women using estrogen
therapy. Both the AKR1C4 and the CYP1B1 polymorphisms
predicted mammographic density change in the combined
estrogen and progestin therapy group (P < 0.05). In particular,
the eight women carrying one or two low-activity AKR1C4 Val
alleles showed a significantly greater increase in MPD (16.7%
and 29.3%) than women homozygous for the Leu allele (4.0%).
Conclusion Although based on small numbers, these findings
suggest that the magnitude of the increase in mammographic
density in women using combined estrogen and progestin
therapy may be greater in those with genetically determined
lower activity of enzymes that metabolize estrogen and
progesterone.
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Introduction
There is growing evidence that combined estrogen and pro-
gestin therapy (EPT) increases the risk of breast cancer more
than estrogen therapy (ET) alone [1-6]. One important
AKR1C4 = aldo-keto reductase 1C4; BMI = body mass index; COMT = catechol-O-methyltransferase; CYP1B1 = cytochrome P450 1B1; EPAT = 
Estrogen in the Prevention of Atherosclerosis Trial; EPT = estrogen and progestin therapy; ET = estrogen therapy; HT = hormone therapy; MPD = 
mammographic percentage density; UGT1A1 = UDP-glucuronosyltransferase 1A1; WELL-HART = Women's Estrogen–Progestin Lipid-Lowering 
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question is whether we can identify subgroups of women who
are at a particularly greater risk of developing breast cancer if
they use EPT or ET. Mammographic percentage density
(MPD) is a strong independent breast cancer risk factor [7-10]
and increases when women commence EPT. On average the
change is 4 to 5% [11]; however, a sub-group of about 25%
(range 10 to 40%) of women starting EPT undergo a substan-
tial increase in MPD of at least 10% or an upgrade in the four-
level Wolfe classification [12-17].
Although it is not known which factors modify change in MPD
in ET or EPT users, it is important to identify such factors
because they might also modify the increase in risk of breast
cancer associated with ET or EPT. Data from the Postmeno-
pausal Estrogen and Progestin Interventions trial showed that
the increase in serum estrone is a strong predictor of MPD
increase in women randomized to EPT [18], suggesting that
factors affecting the absorption or metabolism of EPT are
important. As a next step, we decided to investigate whether
known or suspected functional variants in genes involved in
hormone metabolism would predict changes in MPD in
women randomized to ET and EPT. We selected genes whose
products are known to modulate important aspects in estro-
gen metabolism such as catechol-O-methyltransferase
(COMT), cytochrome P450 1B1 (CYP1B1) and UDP-glu-
curonosyltransferase 1A1 (UGT1A1)), or in progesterone
metabolism (aldo-keto reductase 1C4 (AKR1C4)). As far as
we know, this is the first study to investigate genetic determi-
nants of MPD changes in women randomized to ET, EPT or
placebo.
Materials and methods
Study subjects
Subjects were drawn from two randomized, double-blind, pla-
cebo-controlled studies [19,20], conducted by the Athero-
sclerosis Research Unit at the Keck School of Medicine of the
University of Southern California.
The Estrogen in the Prevention of Atherosclerosis Trial (EPAT)
[19] was a clinical trial conducted in postmenopausal women
aged 45 years or older recruited from direct advertising. Eligi-
ble women had a serum estradiol level of less than 20 pg/ml
and a fasting plasma low-density lipoprotein cholesterol of at
least 130 mg/dl. Exclusion criteria were: use of postmenopau-
sal hormone therapy for more than 10 years or within the pre-
vious month of the first screening visit; history of breast or
gynecologic cancer; life-threatening disease with a prognosis
of less than 5 years; fasting triglyceride level 400 mg/dl or
more; high-density lipoprotein level less than 30 mg/dl; diasto-
lic blood pressure more than 110 mmHg; current smoker;
untreated thyroid disease; renal insufficiency (serum creatinine
more than 2.5 mg/dl); fasting blood glucose more than 200
mg/dl. The 222 subjects enrolled in this study were rand-
omized to receive either 1 mg/day of micronized 17β-estradiol
(ET) or placebo over a period of 2 years.
The Women's Estrogen–Progestin Lipid-Lowering Hormone
Atherosclerosis Regression Trial (WELL-HART) [20] was con-
ducted in postmenopausal women aged 50 to 75 years with
angiographically demonstrable coronary artery disease. Partic-
ipants were recruited from five cardiac catheterization labora-
tories in Los Angeles County that serve patients with diverse
backgrounds. Other criteria for inclusion and exclusion were
as in EPAT except that smokers of fewer than 15 cigarettes a
day were not excluded from participation in WELL-HART. A
total of 226 subjects were randomized to receive either 1 mg/
day of micronized 17β-estradiol with medroxyprogesterone
acetate (MPA) at 5 mg/day for days 19 to 30 each month
(EPT), ET or matching placebo over a period of 3 years [20].
In the present study, we included all subjects who had partic-
ipated in EPAT or WELL-HART for a minimum of 12 months,
who had a current US telephone number and a mammogram
within the 18 months before randomization that was at least 2
months after any previous episodes of postmenopausal hor-
mone use based on patient-reported date of cessation or, if
unavailable, patient response to screening interview question
about use of any hormone therapy (HT) use in the previous
month, and who did not have breast implants or a history of
breast cancer between randomization and the follow-up mam-
mogram. Potentially eligible women who were willing to partic-
ipate in this mammography density sub-study signed a written
informed consent form and provided a blood sample or, if they
lived outside the greater Los Angeles area, a buccal cell sam-
ple. The study protocol was approved by the Institutional
Review Board at the University of Southern California.
Of the 222 subjects randomized in EPAT, 150 (68%) women
were assessed as eligible for recruitment to the present study.
The reasons why 72 women were not eligible for the current
study were as follows: loss to follow-up (n = 27), death (n =
1), withdrawal from original trial (n = 42), breast implants (n =
1), and breast cancer diagnosed during the trial (n = 1). Of
these 150 eligible women, we successfully contacted 149,
and 146 (97%) consented and provided a blood (n = 131) or
buccal (n = 15) specimen. An appropriately timed set of mam-
mograms was available for 127 of these participants (85% of
subjects contacted).
Of the 226 subjects randomized in WELL-HART, 163 (72%)
were eligible for recruitment. The reasons why 63 women
were not eligible for the current study were as follows: loss to
follow-up (n = 16), death (n = 10), withdrawal from original
trial (n = 34), breast cancer diagnosed during the trial (n = 1),
and not competent to sign informed consent (n = 2). We suc-
cessfully contacted 155 of the 163 eligible women; 140
(89%) of these consented and provided a blood (n = 134) or
buccal (n = 6) specimen. Mammograms were available for
105 of these women (68% of subjects contacted).Available online http://breast-cancer-research.com/content/7/3/R336
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Reasons for non-participation among eligible subjects were as
follows: telephone contact unsuccessful (EPAT 1, WELL-
HART 8), patient refusal (EPAT 3, WELL-HART 15), and spec-
imen stored incorrectly (EPAT 1). Problems encountered in
retrieving mammograms were as follows: baseline mammo-
gram not eligible (EPAT 5, WELL-HART 25) and mammogram
not located at the facility where it was taken and further track-
ing was unsuccessful (EPAT 10, WELL-HART 9). No follow-
up mammogram was available for three EPAT subjects, and
one WELL-HART subject was excluded because of techni-
cally poor mammographic images (see assessment score
below).
Data collection
DNA samples and genotyping
Genomic DNA was isolated from blood with a QIAamp 96
DNA Blood Kit (Qiagen, Valencia, CA). DNA isolation from
buccal cells in mouthwash was performed with the Puregene
DNA isolation method (Gentra Systems Inc., Minneapolis,
MN). Genotyping for the following single nucleotide polymor-
phisms was performed using the fluorogenic 5'-nuclease
assay (TaqMan Assay) [21]: COMT (Val158Met), CYP1B1
(Val432Leu),  UGT1A1  (<7/≥ 7 TA repeats) and AKR1C4
(Leu311Val). No signal or an indeterminate signal was
recorded for one or two specimens (less than 1%) in assays
for each polymorphism; these results are recorded as missing
and are excluded from our analysis of that gene. Of the 5%
blinded quality-control repeats, each result matched that of the
corresponding specimen in all assays except one for which
one of the controls gave no signal.
Assessment of MPD change
A baseline mammogram performed closest to, but before, the
subject's randomization date and a mammogram obtained 1
year after randomization were used to measure MPD change.
The mean time between the two mammograms was 14.4
months (range 9 to 31), and this was similar in all the treatment
groups. In EPAT the mean time was 13.5 months in the pla-
cebo group and in the ET group 14.4 months (t-test P = 0.27);
in WELL-HART the mean time was 14.9 months in the pla-
cebo group, 15.4 months in the ET group and 14.5 months in
the EPT group (analysis of variance P = 0.64).
All films were scanned at 150 dots per inch with a Cobrascan
CX-812T scanner (Radiographic Digital Imaging Inc., Tor-
rance, CA) with Adobe Image software. Mammographic den-
sity was determined with a computer-assisted validated
method [22] that we have previously found strongly predicts
breast cancer risk [10], and that we have shown identifies
increases in MPD when women commence EPT [11]. One of
us (GU) assessed all the mammograms for absolute density,
and the breast area was measured by a research assistant
trained by GU. MPD was calculated as the absolute dense
area multiplied by 100 divided by the breast area. The correla-
tion of repeated MPD readings performed on a subset of 14
mammograms at different times was 0.95. The density reader
also assigned a 'difficulty assessment score' for each mammo-
gram ranging from 1 to 6, which indicated how difficult it was
to read the scanned image; a score of 1 was 'normal', and a
score of 6 was 'impossible' for technical reasons. Mammo-
grams from one WELL-HART patient were scored as 6, and
this patient was excluded from the analysis. Scores of 4 or 5
were recorded for 31 of 233 patients (13.3%). This number
did not vary significantly by study group, timing of mammo-
gram (before versus after treatment) or treatment arm (P >
0.45 for all).
Statistical analysis
We used general linear models to determine the least-square
mean change in MPD for subjects in each treatment group
overall and by genotype for each trial independently, and with
the two trials combined. We adjusted for factors known or sus-
pected to be associated with changes in mammographic den-
sity, namely race (White, African American, Latina, Asian/
Pacific Islander), body mass index (BMI) at baseline (kg/m2),
change in BMI on trial, age at baseline mammogram (years)
and MPD at baseline and any past use of ET or EPT (ever/
never). A multiplicative genotype × treatment interaction term
was also included in the model to test for genotype differences
in the treatment-related change in MPD. For our key findings
we also report conservative adjustments of the significance
levels by using the Bonferroni technique (36 comparisons,
Bonferroni-adjusted α level = 0.0014).
The laboratory personnel and the mammographic density
assessor were blinded to treatment and study assignment.
The SAS statistical software package (SAS Institute Inc.,
Cary, NC) was used for all statistical analyses.
Results
Subject characteristics
The distribution of baseline characteristics for the 232 sub-
jects included in this study was similar to that of the parent tri-
als, except that the WELL-HART participants included in this
study were more likely to have had an education beyond high
school (52%) than the WELL-HART participants not included
(32%; P = 0.0003). However, education level was not associ-
ated with mammographic density at baseline or change in den-
sity. Within each trial, baseline characteristics including age,
parity, BMI, family history of breast cancer, education and gen-
otype were similar across treatment groups, except that within
WELL-HART the racial distribution differed significantly by
treatment assignment (P = 0.01).
There were several differences between the two trials, reflect-
ing the differences in the inclusion criteria and recruitment
strategies. WELL-HART subjects were statistically signifi-
cantly older, less educated, more obese, of higher parity, less
likely to have used postmenopausal hormones and more
racially diverse than EPAT subjects (Table 1). Three of theseBreast Cancer Research    Vol 7 No 3    Lord et al.
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factors – age, parity and BMI – are known to be independently
and inversely associated with mammographic density [7] and,
as expected from these differences, the mean MPD at baseline
was significantly lower in WELL-HART subjects than in EPAT
subjects (WELL-HART 10.6%; EPAT 20.3%; P = 0.0001).
However, change in MPD did not vary with MPD at baseline
(Pearson correlation coefficient – 0.06, P = 0.33; Spearman
correlation coefficient 0.03, P = 0.64).
The allelic frequencies for all genes were in Hardy–Weinberg
equilibrium across both trials with the exception of CYP1B1,
which showed statistically significant variation by ethnicity.
Because Hardy–Weinberg equilibrium was maintained within
each ethnic group, a systemic genotyping problem with this
locus is unlikely.
Change in MPD by treatment arm
On average, women assigned to placebo did not exhibit any
change in MPD from baseline (Table 2). Women assigned to
ET in each trial showed a similar 4 to 5% increase in MPD over
placebo in each trial (EPAT P = 0.0001, WELL-HART P =
0.02). Women assigned to EPT in WELL-HART exhibited the
greatest mean change in MPD (7.8%); this was statistically
significantly greater than placebo (P = 0.0005) but not signif-
icantly different from the ET groups (P = 0.32). To determine
whether this was due to a change in breast area or in the
amount of dense tissue in the breast (absolute density), we
examined the effect of treatment on changes in dense area
and changes in the total breast area. The treatment effect was
observed when the analysis was undertaken for change in
mammographic absolute density. The adjusted mean change
in absolute density was greatest in women assigned to EPT
(10.5 cm2) in comparison with women assigned to placebo (-
0.27 cm2,  P  = 0.005) but not significantly different from
women assigned to ET (9.4 cm2, P = 0.76). No treatment
effect was observed on change in breast area (P = 0.31). The
remaining analyses are therefore restricted to changes in
MPD.
Overall, one subject (1%) assigned to placebo showed a 10%
increase in MPD over 12 months, compared with 17% of sub-
Table 1
Baseline characteristics by study and treatment group in women from the EPAT and WELL-HART trials
Characteristic EPAT (n = 127) WELL-HART (n = 105)
Placebo (n = 57) ET (n = 70) P Placebo (n = 37) ET (n = 34) EPT (n = 34) P* P†
Age at baseline mammogram, years (mean ± SEM) 62.3 ± 1.0 60.2 ± 0.8 0.10 64.7 ± 1.0 61.8 ± 1.2 64.1 ± 1.1 0.15 0.005
Years since menopause at baseline (mean ± SEM) 15.1 ± 1.4 12.5 ± 1.0 0.12 18.6 ± 1.6 15.9 ± 1.4 19.5 ± 1.9 0.28 0.001
Number of deliveries (live and stillbirths) (mean ± 
SEM)
2.4 ± 0.2 2.3 ± 0.2 0.75 4.5 ± 0.6 3.6 ± 0.4 4.1 ± 0.5 0.47 0.0001
Race, n (%)
White, non-latina 34 (59.7) 40 (57.1) 12 (32.4) 7 (20.6) 14 (41.2)
Black, non-latina 6 (10.5) 10 (14.3) 4 (10.8) 10 (29.4) 5 (14.7)
Latina 10 (17.5) 13 (18.6) 20 (54.1) 9 (26.5) 11 (32.4)
Asian or Pacific Islander 7 (12.3) 7 (10.0) 0.91 1 (2.7) 8 (23.5) 4 (11.8) 0.01‡ 0.0005
Education, n (%)
High school graduate or less 8 (14.0) 9 (12.9) 20 (54.1) 15 (44.1) 15 (44.1)
Trade or business school/some college 29 (50.9) 33 (48.6) 11 (29.7) 12 (35.3) 13 (38.2)
Bachelor's degree or more 20 (35.1) 27 (38.6) 0.92 6 (16.2) 7 (20.6) 6 (17.7) 0.90 0.0001
Family history of breast cancer (first-degree 
relative), n (%)
9 (15.8) 6 (8.6) 0.21 2 (5.4) 7 (20.6) 3 (8.8) 0.14‡ 0.91
Age at menarche, years (mean ± SEM) 12.7 ± 0.2 12.6 ± 0.2 0.86 12.7 ± 0.3 12.8 ± 0.3 13.3 ± 0.3 0.32 0.21
Ever used postmenopausal hormones, n (%) 36 (63.2) 42 (60.0) 0.72 13 (35.1) 15 (44.1) 21 (61.8) 0.08 0.02
BMI, kg/m2 (mean ± SEM) 28.7 ± 0.7 28.7 ± 0.7 0.96 30.8 ± 1.0 31.4 ± 1.0 30.2 ± 1.1 0.73 0.007
Mammographic density at baseline, % (mean ± 
SEM)
17.8 ± 2.3 22.3 ± 1.9 0.13 7.9 ± 1.8 10.8 ± 2.1 13.3 ± 2.3 0.19 0.0001
*Comparison of characteristics by treatment group, χ2 test for comparison of categorical variables, analysis of variance for comparison of means; 
†comparison of characteristics between trials (EPAT versus WELL-HART), χ2 test for comparison of categorical variables, analysis of variance for 
comparison of means; ‡Fisher's exact test. EPAT, Estrogen in the Prevention of Atherosclerosis Trial; ET, 1 mg/day micronized 17β-estradiol; EPT, 1 
mg/day micronized 17β-estradiol with 5 mg/day medroxyprogesterone acetate for days 19 to 30 each month; WELL-HART, Women's Estrogen–
Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial.Available online http://breast-cancer-research.com/content/7/3/R336
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jects assigned to ET and 32% assigned to EPT. Increases in
MPD in the EPT arm were apparent within each ethnic group.
Genetic determinants of MPD change
Because there was no statistical significant heterogeneity in
the ET effect between the two studies (MPD change 4.0%
and 5.6% respectively, P for homogeneity of effect = 0.76),
we combined the results of both studies to provide more
power to investigate a treatment interaction between geno-
type and change in MPD. There was no statistically significant
association between genotype and baseline MPD in either trial
or in the trials combined (data not shown). Overall there was
also no evidence for an association between change in MPD
and genotype in women randomized to ET (Table 3). However,
in EPAT there was a statistically significant increase in MPD in
women in the ET arm who possessed the COMT Met/Met
genotype compared with those with the Val/Val genotype (P =
0.02, P  for ET–genotype interaction = 0.17), but no such
association was observed in the WELL-HART ET arm.
Two of the genes studied modified the MPD changes associ-
ated with EPT use. Both the Val/Val and Leu/Val genotypes of
the AKR1C4 gene were associated with a statistically signifi-
cant increase in density compared with the Leu/Leu genotype
among women assigned to EPT (P = 0.0001, 0.0007, respec-
tively; P = 0.004, 0.03, respectively, corrected for 36 multiple
comparisons). However, there were only seven women heter-
ozygous and one woman homozygous for the Val allele. The
AKR1C4–treatment interaction was statistically significant (P
= 0.001). When analyses were restricted to the WELL-HART
study, the probabilities for the Val/Val and Leu/Val genotypes
in comparison with the Leu/Leu genotypes were P = 0.001,
0.003, respectively, and the treatment interaction P = 0.05).
There was also a statistically significant association between
the CYP1B1 genotype and MPD change among women tak-
ing EPT. The Leu/Leu genotype of CYP1B1 was associated
with a statistically significantly greater MPD change in women
assigned to EPT than the Val/Val genotype (P = 0.03, not
significant after correction for multiple comparisons). How-
ever, heterozygotes for this polymorphism showed the small-
est increase in MPD. The interaction between ET/EPT and
CYP1B1 was statistically significant (P = 0.0004).
The results were similar when analyses were restricted to the
WELL-HART study; the probability for the Leu/Leu genotype
was P = 0.09 and treatment interaction P = 0.006.
The results for the COMT gene and the UGT1A1 genes were
also similar when analyses were restricted to the WELL-HART
study (results not shown).
Discussion
In this study we found that women randomized to ET and EPT
had a statistically significant mean increase in MPD over 12
months compared with women assigned to placebo, with the
women assigned to EPT having the greatest mean increase in
MPD. These findings are consistent with those (using the
Table 2
Change in mammographic percentage density by treatment assignment
Treatment Change in mammographic density (%)
Unadjusted mean ± SEM P Adjusted mean ± SEM* P
EPAT
Placebo (n = 57) - 0.7 ± 0.8 Ref. - 0.9 ± 0.9 Ref.
ET (n = 70) 3.4 ± 0.7 0.003 4.0 ± 0.8 0.0001
WELL-HART
Placebo (n = 37) 0.8 ± 1.4 Ref. 0.06 ± 1.7 Ref.
ET (n = 34) 4.8 ± 1.5 0.06 5.6 ± 1.5 0.02
EPT (n = 34) 7.8 ± 1.5 0.001 7.8 ± 1.6 0.0005
P homogeneity of treatment effect between trials 0.76
All women
Placebo (n = 95) - 0.02 ± 0.8 Ref. 0.02 ± 0.8 Ref.
ET (n = 104) 3.9 ± 0.7 0.0003 4.6 ± 0.8 0.0001
EPT (n = 34) 7.8 ± 1.3 0.0001 7.2 ± 1.5 0.0001
*Adjusted for mammographic percentage density at baseline, race, age at baseline, years since menopause, past use of hormone therapy, body 
mass index (BMI) at baseline, change in BMI on trial and study group. EPAT, Estrogen in the Prevention of Atherosclerosis Trial; EPT, estrogen 
and progestin therapy; ET, estrogen therapy; WELL-HART, Women's Estrogen–Progestin Lipid-Lowering Hormone Atherosclerosis Regression 
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same reader and same method) from the only published pla-
cebo-controlled randomized clinical trial with EPT [11]. Inter-
estingly, there was a similar effect of ET in two diverse study
populations in the current study despite significant differences
in MPD at baseline and other potential confounders (age, BMI
and parity) between these two populations. The lack of a sta-
tistically significant difference between the increase in MPD in
the EPT arm and the ET arms might have been due to a small
EPT sample size of 34 subjects.
In data from the Postmenopausal Estrogen and Progestin
Interventions (PEPI) trial, a greater increase in serum estrone
level as a function of treatment was a significant predictor of
MPD increase in women randomized to EPT, but not in women
randomized to ET alone [18]. The PEPI study had no data on
how serum progesterone or progestin levels changed. How-
ever, these results raised the possibility that factors associ-
ated with hormone absorption or metabolism are important
determinants in how the breast tissue reacts to EPT.
Medroxyprogesterone acetate has a similar structure and met-
abolic pathway to progesterone. After medroxyprogesterone
is ingested it undergoes reduction and hydroxylation in the
small intestine [23,24]. After absorption it undergoes further
metabolism in the liver, including 3α-hydroxylation (AKR1C4)
[25]. The Leu311Val polymorphism on AKR1C4 has been
associated with a 66 to 80% decrease in the catalytic activity
of the enzyme [26]. Consistent with this was our finding that
subjects randomized to EPT who were heterozygotes or
homozygotes for this low-activity allele showed significantly
greater increases in MPD than homozygotes for the wild-type
Leu/Leu allele. In addition, the one subject possessing two
copies of the Val allele showed the greatest increase in MPD,
suggesting a potential allelic dosage effect.
A number of studies have investigated the role of estrogen
metabolism on breast cancer risk. The major forms of estro-
gen, namely estrone and estradiol, are hydroxylated into 2-, 4-
or 16-hydroxyestrogens. Initially, much research focused on
the role of 2- and 16-hydroxy metabolites, with most of the
later studies finding no protective effects of a high 2- to 16α-
hydroxyestrone ratio [27-32]. In contrast, newer research sug-
gests that the important question is how much estrogen is
metabolized down the 4-hydroxy pathway, because the 4-
hydroxy products are genotoxic [33]. An important enzyme
involved in the 4-hydroxylation of estrogen is CYP1B1 [34].
After hydroxylation, these estrogens may further undergo sul-
fonation, glucuronidation (UGT1A1) or O-methylation
(COMT), which increases the water solubility and therefore
the excretion of these metabolites [35].
Table 3
Least-square mean change in mammographic percentage density by genotype and treatment arm, adjusted
Genotype Placebo ET EPT
Mean (N)S E M P* Mean (N)S E M P Mean (N)S E M PP †
COMT Val158Met
Val/Val - 0.1 (30) 1.4 Ref. 3.7 (30) 1.4 Ref. 8.0 (12) 2.3 Ref.
Val/Met 0.5 (45) 1.2 0.74 4.3 (48) 1.1 0.72 6.2 (19) 1.9 0.54
Met/Met - 0.6 (19) 1.8 0.82 6.0 (25) 1.6 0.27 9.8 (3) 4.5 0.72 0.77
CYP1B1 Val432Leu
Val/Val - 0.7 (15) 1.9 Ref. 4.7 (23) 1.6 Ref. 6.9 (7) 2.9 Ref.
Leu/Val - 0.01 (42) 1.2 0.75 5.8 (44) 1.2 0.57 1.3 (13) 2.1 0.11
Leu/Leu 0.9 (36) 1.2 0.47 3.6 (37) 1.2 0.61 14.5 (13) 2.1 0.03 0.0004
UGT1A1
<7/<7 TA repeats 0.3 (37) 1.3 Ref. 5.7 (50) 1.1 Ref. 7.1 (18) 1.9 Ref.
<7/≥ 7 TA repeats - 0.5 (43) 1.2 0.60 3.3 (39) 1.3 0.15 8.7 (12) 2.3 0.57
≥ 7/≥ 7 TA repeats 0.6 (14) 2.1 0.92 4.4 (14) 2.1 0.58 5.4(3) 4.6 0.74 0.77
AKR1C4 L311V
Leu/Leu - 0.3 (72) 0.9 Ref. 4.3 (79) 0.8 Ref. 4.0 (25) 1.6 Ref.
Leu/Val 1.5 (21) 1.6 0.30 5.5 (25) 1.5 0.47 16.7 (7) 2.8 0.0001
Val/Val 0.6 (1) 0.90 (0) 29.3 (1) 0.0007 0.001
Figures are adjusted for race, age at baseline, years since menopause, body mass index (BMI) at baseline, change in BMI on trial, mammographic 
percentage density at baseline, past use of hormone therapy and study group.
*Analysis of covariance P for comparison of means; †analysis of covariance P for ET/EPT × genotype interaction. AKR1C4, aldo-keto reductase 
1C4; COMT, catechol-O-methyltransferase; CYP1B1, cytochrome P450 1B1; EPT, estrogen and progestin therapy; ET, estrogen therapy; 
UGT1A1, UDP-glucuronosyltransferase 1A1.Available online http://breast-cancer-research.com/content/7/3/R336
R342
The CYP1B1 Val432Leu polymorphism has been associated
with breast cancer in an Asian study [36] but not in two stud-
ies of Caucasians [36-38]. A Swedish case-control study
observed an increased risk of breast cancer in Leu/Leu carri-
ers in comparison with Val/Val carriers in women who had
used HT for longer than 4 years [39]. However, a cross-sec-
tional study showed no association between CYP1B1 geno-
type and mammographic density in women using HT [40]. In
our study the CYP1B1 Val432Leu polymorphism predicted
the change in MPD in women randomized to EPT, although
this finding was no longer statistically significant after adjust-
ment for multiple comparisons. There was no consistent dose
effect with Leu alleles because heterozygotes had the lowest
density increase. Our findings are therefore consistent with
the available data and we cannot exclude the possibility that
this gene might have a role in gene–environment interactions
in EPT users.
The enzyme encoded by COMT is responsible for the conju-
gation and inactivation of catechol estrogen. A Val158Met pol-
ymorphism has been associated with lower activity of this
enzyme [41] and is associated with increased plasma levels of
17β-estradiol in postmenopausal women taking ET [42]. In a
recent cross-sectional study we reported a statistically signifi-
cant association between the Met/Met allele and MPD in cur-
rent users of HT (ET) [43]. In the present study, women
assigned to ET in the EPAT study who possessed this high-
risk variant showed a statistically significant increase in MPD
compared with Val/Val homozygotes, but this effect was not
observed in the ET arm of WELL-HART, in which the partici-
pants all had angiographically demonstrable coronary artery
disease. We found no evidence that the UGT1A1 polymor-
phism was associated with MPD increase in women assigned
to ET or EPT.
Strengths of our study included the randomized design, the
use of a validated method and an experienced reader to
assess mammographic density. However, there were several
limitations. Study subjects represented only 57% and 47% of
those originally randomized to EPAT and WELL-HART,
respectively, because several of the participants in the parent
trials had died or were lost to follow-up after the completion of
the original trial. The small sample size, particularly in the EPT
arm, limited our power to detect gene–environment interac-
tions. However, it is unlikely that this could have biased our
results and caused the apparent associations between geno-
type and change in MPD with treatment, because the most
likely effect of this loss to follow-up would be to obscure a true
association by a loss of statistical power. It is possible that
some or all of the associations observed represent chance
findings (false positives) due to multiple testing; however, our
main findings of the effect of HT on MPD and the interaction
with AKR1C4 genotype are statistically significant after con-
servative correction with Bonferroni's technique.
Another limitation is that women assigned to EPT and a subset
of those on ET were drawn from a select study population with
diagnosed cardiovascular disease and poor general health
(the WELL-HART study). It is therefore unclear to what extent
our findings can be generalized to populations with better
health. The fact that we found that the COMT polymorphism
modified the effect of ET on MPD in the EPAT study but not in
the WELL-HART study suggests that the women with angio-
graphically detected heart disease in the WELL-HART study
might have been different. However, similar MPD changes
w e r e  o b s e r v e d  i n  t h e  E T  a r m s  o f  b o t h  t h e  E P A T  a n d  t h e
WELL-HART study. Further, our finding of the magnitude of
the increase in MPD associated with EPT use was similar to
that recently reported from a trial of EPT use [11]. Thus,
although we cannot exclude the possibility that the observed
modifying effects of the AKR1C4 genotype were due to some
other characteristic among these women with angiographi-
cally detectable heart disease, we find it unlikely.
Conclusion
This is the first study to investigate genetic determinants of
MPD changes in women randomized to ET, EPT or placebo.
Although plausible, it is still unknown whether women with the
greatest increase in MPD in response to EPT are at higher risk
for breast cancer associated with EPT use than other women.
Much research in this area remains to be done, but our find-
ings from this pilot study suggest that the magnitude of the
increase in MPD might be greater in women with a genetically
determined lower activity of some enzymes that metabolize
EPT.
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